Clinical trials
Phase 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| Pfizer | 2 |
| University of Jena | 2 |
| Ariad Pharmaceuticals | 1 |
| Ascentage Pharma Group Inc. | 1 |
| Bristol-Myers Squibb | 1 |
| European LeukemiaNet | 1 |
| European Society for Blood and Marrow Transplantation | 1 |
| Fred Hutchinson Cancer Center | 1 |
| German CML Study Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 24 |
| Leukemia | 10 |
| Bone Marrow Diseases | 4 |
| Leukemia, Myeloid | 4 |
| Leukemia, Myeloid, Chronic-Phase | 4 |
| Hematologic Neoplasms | 3 |
| Myeloproliferative Disorders | 3 |
| Philadelphia Chromosome | 3 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Hematologic Diseases | 2 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.